Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Cullinan Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +3 vs. Q1 2023
- Shares held
- 36.9M
- +4.62M (+14.3%) vs. Q1 2023
- Total value
- $397.3M
- +$67.8M (+20.6%) vs. Q1 2023
- New holders
- 23
- 30 more added
- Sold out
- 20
- 38 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CGEM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 183 | $1.30B |
| Q1 2026 | 174 | $931.0M |
| Q4 2025 | 153 | $653.8M |
| Q3 2025 | 145 | $362.2M |
| Q2 2025 | 144 | $471.4M |
| Q1 2025 | 149 | $489.6M |
| Q4 2024 | 147 | $798.8M |
| Q3 2024 | 137 | $1.09B |
| Q2 2024 | 135 | $1.10B |
| Q1 2024 | 113 | $670.8M |
| Q4 2023 | 113 | $375.6M |
| Q3 2023 | 106 | $344.0M |
| Q2 2023 | 106 | $397.3M |
| Q1 2023 | 103 | $329.5M |
| Q4 2022 | 97 | $397.7M |
| Q3 2022 | 100 | $474.7M |
| Q2 2022 | 89 | $481.7M |
| Q1 2022 | 82 | $386.3M |
| Q4 2021 | 75 | $559.7M |
| Q3 2021 | 66 | $762.3M |
| Q2 2021 | 71 | $828.5M |
| Q1 2021 | 70 | $1.30B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Cullinan Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 2,027,406 | $21.8M | 0.00% | −527,582−20.6% | Reduced |
| BlackRock Inc. | 2,104,069 | $22.6M | 0.00% | −151,528−6.7% | Reduced |
| Franklin Resources Inc | 2,334,086 | $25.1M | 0.01% | +1,544,948+195.8% | Added |
| BVF Inc | 3,196,701 | $34.4M | 0.96% | 00.0% | Unchanged |
| CHI Advisors LLC | 3,414,189 | $36.7M | 11.15% | +64,729+1.9% | Added |
| MPM Oncology Impact Management LP | 7,648,268 | $82.3M | 16.57% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −265,032−100.0% | Sold out |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −246,410−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −120,109−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −48,622−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −27,122−100.0% | Sold out |
| Tejara Capital Ltd | 0 | $0 | 0.00% | −23,600−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −15,502−100.0% | Sold out |
| CM Wealth Advisors LLC | 0 | $0 | 0.00% | −14,775−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −14,018−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −12,945−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −12,497−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −11,066−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −11,044−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Caxton Associates LP | 0 | $0 | 0.00% | −10,541−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −1,084−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −55,170−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −171−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −36−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −23−100.0% | Sold out |